Displaying 155 (all) recruiting clinical trials.
-
NVL-520-01: A Phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced NSCLC and other solid tumors (ARROS-1).
You can participate in this study if you are diagnosed with advanced non-small cell lung cancer, and other advanced solid cancers. The purpose of this ...
-
An open-label phase I dose escalation expansion study of MGY825 in adult patients with advanced non-small cell lung cancer
This study wants to figure out if a new medicine called MGY825 is safe and helpful for patients with advanced non-small cell lung cancer. They ...
-
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This is a study of a drug called LOXO-435 for patients with advanced solid tumors, specifically focusing on metastatic urothelial cancer (mUC) that has a ...
-
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA
A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA -
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
This study wants to see if a medicine called disitamab vedotin (designed to go straight to cancer cells and slow down or shrink the cancer ... -
A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
This research study is testing two treatments for a type of bladder cancer (Urothelial Carcinoma that expresses HER2) that has spread or is hard to ...
-
A Phase 2a Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
This is a medical study testing a drug called FF-10832 alone and with another medicine called pembrolizumab for patients with advanced solid tumors. First, patients ...
-
Randomized Open-label Multicenter Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
This is a study to compare two medicines (repotrectinib and crizotinib) for patients with a type of lung cancer called ROS1-positive NSCLC (Non-small Cell Lung ...
-
A Phase 1/1b First-In-Human Multi-Part Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable Recurrent or Metastatic) Solid Tumors
This is a study is testing a new drug called DF6215 on patients with tough-to-treat (unresectable, recurrent or metastatic) solid tumors. The goal is to ...
-
A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors
This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it ...